It's not normal to feel like your period controls your life.' When I heard those words, it was the final push I needed to ...
But while you’re navigating all of that and trying to be more mindful of your drinking habits (maybe you're even part of the ...
Do you feel unusually tired or warm following the days of ovulation? These are common changes that you may experience in your luteal phase. You may feel your energy drop or be sleepy. But why does it ...
The hysterical, hormonal woman – a stereotype you thought had died – is suddenly trending on social media. Only now it’s women calling out their own crazy. Are we validating a collective experience – ...
BASEL, Switzerland and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Noema Pharma AG today announced positive topline results from a Phase 2a, open-label study evaluating cendifensine in menopausal women ...
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone’s clinical ...
We may earn commission from links on this page, but we only recommend products we love. Promise. The menstrual cycle is the 28 (ish) day process of hormonal changes that prepares a woman’s body for a ...
Reunion Neuroscience’s psychedelic has reduced the symptoms of postpartum depression in a phase 2 study, setting up the biotech to launch a late-stage trial next year. The drug in question is RE104, a ...
Premenstrual symptoms are distressing for up to 20% of reproductive-aged women and are associated with impairment in interpersonal or workplace functioning for at least 3-8%. Typical symptoms of ...
Ubrogepant during the prodromal phase of migraine may alleviate common prodromal symptoms. Peter J. Goadsby, M.B.B.S., M.D., Ph.D., from King’s College London, and colleagues conducted a phase 3, ...
Administration of ubrogepant during the prodromal phase of migraine may alleviate symptoms such as photophobia, phonophobia, and cognitive dysfunction. HealthDay News — Ubrogepant during the prodromal ...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) ...